Gene therapy targeting the blood-brain barrier

Area of Science:

• Neuroscience
• Biotechnology
• Pharmacology

Background:

• The central nervous system (CNS) is protected by the blood-brain barrier (BBB), which restricts the passage of large molecules.
• This barrier poses a significant challenge for delivering therapeutics like antibodies, proteins, and viral vectors to treat CNS disorders.

Purpose of the Study:

• To explore strategies for overcoming the BBB to enable CNS drug delivery.
• To evaluate the potential of utilizing brain endothelial cells as in situ production sites for therapeutic proteins.

Main Methods:

• Review of existing strategies for BBB penetration, including receptor-mediated transcytosis using ligands like transferrin receptor (TfR).
• Conceptual exploration of producing therapeutic proteins directly within the endothelial cells forming the BBB.

Main Results:

• Receptor-mediated transcytosis shows promise but can be complex to implement.
• Producing therapeutics within endothelial cells offers a potentially simpler alternative for direct CNS supply.

Conclusions:

• The BBB is a critical obstacle for CNS therapeutics.
• Endothelial cells of the BBB present a viable and direct platform for in situ therapeutic protein production, facilitating CNS delivery.